Geron (FRA:GON) FFO


FRA:GON Geron Corp FRA:GON
39 GF Score
Price €1.18
GF Value €6.00
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Geron FFO?

FFO (Funds from operations) only applies to REITs.

FRA:GON
39GF Score
Geron Corp FRA:GON
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Geron (FRA:GON) Overvalued in 2026?

Based on GuruFocus' analysis, Geron stock appears to be undervalued. The current stock price of €1.18 is trading 80.4% below its estimated GF Value™ of €6.00. GuruFocus considers Geron to be Possible Value Trap.

Key valuation signals for FRA:GON:

  • FFO:
  • GF Value™: €6.00 vs. price of €1.18 (80.4% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the FRA:GON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Geron Business Description

Address 919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
39GF Score

Get the complete analysis for FRA:GON

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.18
Price
€6.00
GF Value